Anti-Helicobacter pylori treatment in children: Adverse events

Only mild adverse events have been observed in H pylori treatment trials in children, but the manner in which adverse events were recorded and the occurrence of adverse events varied greatly between studies (unpublished data). Adverse events were observed in 0% to 34% of subjects given a dual therapy over one to six weeks of treatment, and in 0% to 80% of subjects given a triple therapy for one to three weeks (unpublished data). In head-to-head studies, triple therapies did not result in more adverse events compared with dual therapies. In one study , there were more adverse events with dual therapy using clarithromycin and amoxicillin compared with PPI-CA (34% versus 14%; P<0.0001). Although there has been some concern over the use of bismuth salts in children and its association with encephalopathy, bismuth levels were found to be well below toxic levels in children.

Resistance of H pylori to commonly used antibiotics is a recognized problem. Marked geographical variation for primary drug resistance to H pylori in children was observed (Figures 2 and 3). Primary resistance to metronidazole ranged from 13% to 57% in Europe , 39% in Australia, 0% to 24% in Japan, 9% in Taiwan and 45% in the United States. Once you have read all the information given above, you may be thinking about getting the drug that will solve the problem. At our canadian pharmacy family viagra you will find best deals on the medicine required getting it delivered very soon.

Figure 2) Prevalence of primary metronidazole resistance in children. US United States

Figure 3) Prevalence of primary clarithromycin resistance in children. US United States